ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO241

Onconephrology and AKI: A University Hospital Experience

Session Information

Category: Onconephrology

  • 1700 Onconephrology


  • Valenca, Andrea C.E.P, Hospital das Clinicas, Recife, Pernambuco, Brazil
  • Oliveira, Alline, Hospital das Clinicas, Recife, Pernambuco, Brazil
  • Nascimento, Joseph Lopes, Hospital das Clinicas, Recife, Pernambuco, Brazil
  • Lacerda, Thiago Martins, Hospital das Clinicas, Recife, Pernambuco, Brazil
  • Feijo de Melo, Klebson Fellipe, Hospital das Clinicas, Recife, Pernambuco, Brazil
  • Alves, Italo Rafael Correia, Hospital das Clinicas, Recife, Pernambuco, Brazil
  • Gueiros, Ana Paula, Hospital das Clinicas, Recife, Pernambuco, Brazil

Acute kidney injury (AKI) is prevalent in cancer patients and associated with poor outcomes. The aim of this study was to assess the clinical profile and outcomes of patients with cancer and AKI followed up in our onconephrology department.


This was a cross-sectional, retrospective study. The medical records of AKI patients were reviewed from January 2018-December 2022. AKI was diagnosed according to KDIGO. COVID-19 patients were excluded.


We assessed 340 patients, 50% were male, with a median age of 62 years. The mean follow-up was 15 days. Seventy-eight percent of the patients presented with a solid tumor. The main associated cancers were: digestive tract (27.6%), cervix (15.3%) and lymphoma (12.4%). Comorbidities: hypertension (50%), diabetes mellitus (25%), and chronic kidney disease (24%). Around a third of patients were in ICU and 34% had sepsis. The AKI types were: intrinsic renal (38%), prerenal (31%) and obstructive (27%). Most patients (72%) were non-oliguric. Laboratory tests: creatinine (Cr mg/dL) on admission (CrA) 1.6 and Cr at the first nephrology visit (CrN) 2.7. Hyponatremia (sodium <135 mg/dL) was observed in 53% of patients. The median level of hemoglobin was 8.9 g/dL and albumin 2.9 g/dL. Renal replacement therapy (RRT) was required for 37% of patients. Patients on RRT differed from those who did not, by age (59 x 64; p=0.006), being in ICU (64 x 40; p<0.001), CrA (2.25 x 1.57; p=0.002), CrN (3.7 x 2.5 ; p<0.001), sepsis (50% x 24%; p<0.001), urine output (mL) (405 x 1300; p <0.001), sodium (133 x 135; p=0.034), potassium (mg/dL ) (4.8 x 4.5; p= 0.008) and phosphorus (mg/dL) (4.6 x 3.9; p<0.001). In the multivariate analysis, CrN was the only independent risk for RRT (OR 12.6, CI 2.77 – 113; p=0.005). Thirty-five percent of patients died, and mortality was higher in those who underwent RRT (56% vs. 22%, p<0.001). Only 26% of patients fully recovered and 4% remained on RRT.


AKI in cancer patients is associated with high mortality. The clinical profile of cancer patients is unfavorable, with a high prevalence of hyponatremia, anemia and malnutrition. A late referral to a nephrologist is associated with higher rate of RTT and a poor prognosis.